



SWEDEN

Number of new cases

69 261

Number of deaths

25 569

Number of prevalent cases (5-year)

236 266


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	5 122 444	5 096 528	10 218 972
Incidence*			
Number of new cancer cases	37 869	31 392	69 261
Age-standardized incidence rate	334.8	289.1	310.0
Risk of developing cancer before the age of 75 years (cum. risk %)	32.8	27.6	30.1
Top 3 leading cancers (ranked by cases)**	Prostate Colorectum Melanoma	Breast Colorectum Melanoma	Prostate Colorectum Breast
Mortality*			
Number of cancer deaths	13 208	12 361	25 569
Age-standardized mortality rate	92.4	80.0	85.2
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.9	8.3	8.6
Top 3 leading cancers (ranked by deaths)**	Prostate Lung Colorectum	Lung Colorectum Breast	Lung Colorectum Prostate
Prevalence*			
5-year prevalent cases	129 528	106 738	236 266



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Prostate	11 732	31.0%
2nd	Colorectum	4 037	10.7%
3rd	Melanoma	2 697	7.1%
4th	Bladder	2 554	6.7%
5th	Lung	1 978	5.2%
-	Others	14 871	39.3%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Breast	7 452	23.7%
2nd	Colorectum	3 662	11.7%
3rd	Melanoma	2 562	8.2%
4th	Lung	2 463	7.8%
5th	Corpus uteri	1 510	4.8%
-	Others	13 743	43.8%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Prostate	11 732	16.9%
2nd	Colorectum	7 699	11.1%
3rd	Breast	7 452	10.8%
4th	Melanoma	5 259	7.6%
5th	Lung	4 441	6.4%
-	Others	32 678	47.2%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Prostate	11 732	1	16.9	13.1	2 475	3	9.7	0.78	50 760	990.9
Colorectum	7 699	2	11.1	3.6	3 218	2	12.6	1.1	25 443	249.0
Breast	7 452	3	10.8	8.9	1 535	5	6.0	1.3	32 683	641.3
Melanoma	5 259	4	7.6	3.0	536	15	2.1	0.22	21 190	207.4
Lung	4 441	5	6.4	2.2	3 816	1	14.9	1.6	5 528	54.1
Bladder	3 390	6	4.9	1.4	881	7	3.4	0.22	11 624	113.8
Pancreas	2 413	7	3.5	1.1	2 239	4	8.8	0.84	1 926	18.9
NHL	2 375	8	3.4	1.2	866	8	3.4	0.23	7 990	78.2
Kidney	1 718	9	2.5	1.1	622	11	2.4	0.20	6 031	59.0
Leukaemia	1 636	10	2.4	0.87	828	9	3.2	0.27	5 342	52.3
Corpus uteri	1 510	11	2.2	1.6	387	17	1.5	0.23	6 107	119.8
Liver	1 015	12	1.5	0.57	917	6	3.6	0.37	1 213	11.9
Thyroid	936	13	1.4	0.65	96	22	0.38	0.03	3 822	37.4
Brain CNS	926	14	1.3	0.61	763	10	3.0	0.47	4 121	40.3
Multiple myeloma	904	15	1.3	0.46	526	16	2.1	0.17	2 815	27.6
Stomach	871	16	1.3	0.43	550	13	2.2	0.23	1 187	11.6
Lip, oral cavity	816	17	1.2	0.43	248	18	0.97	0.10	2 752	26.9
Ovary	723	18	1.0	0.92	543	14	2.1	0.50	2 376	46.6
Oesophagus	640	19	0.92	0.27	577	12	2.3	0.25	730	7.1
Cervix uteri	561	20	0.81	0.77	238	19	0.93	0.20	2 223	43.6
Testis	391	21	0.56	0.58	8	32	0.03	0.01	1 863	36.4
Gallbladder	249	22	0.36	0.12	164	21	0.64	0.06	308	3.0
Oropharynx	239	23	0.35	0.17	69	25	0.27	0.04	814	8.0
Vulva	222	24	0.32	0.18	96	22	0.38	0.04	735	14.4
Mesothelioma	207	25	0.30	0.10	195	20	0.76	0.06	223	2.2
Hodgkin lymphoma	204	26	0.30	0.14	31	29	0.12	0.01	857	8.4
Larynx	160	27	0.23	0.09	78	24	0.31	0.03	563	5.5
Penis	143	28	0.21	0.14	37	28	0.14	0.03	489	9.6
Salivary glands	93	29	0.13	0.05	50	26	0.20	0.02	333	3.3
Hypopharynx	72	30	0.10	0.04	44	27	0.17	0.02	144	1.4
Vagina	37	31	0.05	0.04	13	30	0.05	0.01	107	2.1
Nasopharynx	28	32	0.04	0.02	13	30	0.05	0.00	107	1.1
All cancers	69 261	-	-	30.1	25 569	-	-	8.6	236 266	-
All cancers excl. NMSC	61 794	-	-	28.8	25 461	-	-	8.6	209 631	-

Data source and methods

Incidence



Country-specific data source: [{"dt_list": "National cancer registry" }]
 Method: National (or sub-national with coverage greater than 50%) rates projected to 2022

Mortality

Country-specific data source: National (WHO) and Eurostat
 Method: National rates projected to 2022

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

